• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病中的反应时间与警觉性。去甲肾上腺素代谢改变的可能作用。

Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism.

作者信息

Stern Y, Mayeux R, Côté L

出版信息

Arch Neurol. 1984 Oct;41(10):1086-9. doi: 10.1001/archneur.1984.04050210084021.

DOI:10.1001/archneur.1984.04050210084021
PMID:6206831
Abstract

Delayed reaction time and diminished vigilance have been observed in Parkinson's disease (PD) but have not been related to biochemical changes in the disease. As norepinephrine is reduced in the brain in PD and this neurotransmitter has been related to attention and learning, we investigated the relationship of neuropsychological measures, including those of reaction time and vigilance, to the norepinephrine metabolite 3-methoxy - 4 - hydroxyphenethyleneglycol (MHPG) in 39 patients with idiopathic PD. The MHPG levels correlated with a measure of general intellectual ability and with performance on reaction time and continuous performance tasks. Our data suggest that altered norepinephrine metabolism may contribute to some aspects of intellectual dysfunction in PD.

摘要

帕金森病(PD)患者存在反应时间延迟和警觉性降低的情况,但这些与该疾病的生化变化并无关联。由于帕金森病患者大脑中的去甲肾上腺素减少,且这种神经递质与注意力和学习有关,我们对39例特发性帕金森病患者进行了研究,以探讨神经心理学指标(包括反应时间和警觉性指标)与去甲肾上腺素代谢产物3-甲氧基-4-羟基苯乙二醇(MHPG)之间的关系。MHPG水平与一般智力能力指标以及反应时间和连续操作任务的表现相关。我们的数据表明,去甲肾上腺素代谢改变可能导致帕金森病患者智力功能障碍的某些方面。

相似文献

1
Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism.帕金森病中的反应时间与警觉性。去甲肾上腺素代谢改变的可能作用。
Arch Neurol. 1984 Oct;41(10):1086-9. doi: 10.1001/archneur.1984.04050210084021.
2
Clinical and biochemical correlates of bradyphrenia in Parkinson's disease.
Neurology. 1987 Jul;37(7):1130-4. doi: 10.1212/wnl.37.7.1130.
3
CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.阿尔茨海默病和帕金森病患者脑脊液中单胺代谢物水平
Arch Neurol. 1985 May;42(5):489-92. doi: 10.1001/archneur.1985.04060050091016.
4
Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease.
Eur Neurol. 1987;26(1):29-34. doi: 10.1159/000116308.
5
Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.帕金森病中体内中枢儿茶酚胺代谢以及认知和运动缺陷
J Neurol Neurosurg Psychiatry. 1983 Oct;46(10):905-10. doi: 10.1136/jnnp.46.10.905.
6
Correlations between cisternal CSF and plasma concentrations of HVA, MHPG, 5-HIAA, DA, and NA.
Biol Psychiatry. 1990 May 15;27(10):1179-82. doi: 10.1016/0006-3223(90)90055-7.
7
Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.人类中枢神经系统中的去甲肾上腺素代谢:利用脑脊液中3-甲氧基-4-羟基苯乙二醇水平的研究
J Neurochem. 1973 Sep;21(3):581-7. doi: 10.1111/j.1471-4159.1973.tb06003.x.
8
Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.血管性帕金森病与帕金森病和对照组脑脊液中 HVA、5-HIAA 和 MHPG 的水平比较。
J Neurol. 2013 Dec;260(12):3129-33. doi: 10.1007/s00415-013-7126-5.
9
Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments.
Neuropsychologia. 1988;26(6):895-902. doi: 10.1016/0028-3932(88)90057-7.
10
Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.选择性抗抑郁药与脑脊液。对去甲肾上腺素和血清素代谢物缺乏特异性。
Arch Gen Psychiatry. 1985 Dec;42(12):1171-7. doi: 10.1001/archpsyc.1985.01790350045009.

引用本文的文献

1
Redefining Non-Motor Symptoms in Parkinson's Disease.重新定义帕金森病的非运动症状
J Pers Med. 2025 Apr 26;15(5):172. doi: 10.3390/jpm15050172.
2
N200 and P300 component changes in Parkinson's disease: a meta-analysis.帕金森病 N200 和 P300 成分变化的荟萃分析。
Neurol Sci. 2022 Dec;43(12):6719-6730. doi: 10.1007/s10072-022-06348-6. Epub 2022 Aug 18.
3
Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease.冲突处理中的补偿性多巴胺-胆碱能相互作用:来自帕金森病患者的证据。
Neuroimage. 2019 Apr 15;190:94-106. doi: 10.1016/j.neuroimage.2018.01.021. Epub 2018 Jan 11.
4
Orbitofrontal (18) F-DOPA Uptake and Movement Preparation in Parkinson's Disease.帕金森病眶额部(18)F - 多巴摄取与运动准备
Parkinsons Dis. 2015;2015:180940. doi: 10.1155/2015/180940. Epub 2015 Jun 11.
5
Targeting impulsivity in Parkinson's disease using atomoxetine.使用托莫西汀治疗帕金森病中的冲动行为
Brain. 2014 Jul;137(Pt 7):1986-97. doi: 10.1093/brain/awu117. Epub 2014 Jun 3.
6
Behavioral toxicology of cognition: extrapolation from experimental animal models to humans: behavioral toxicology symposium overview.认知行为毒理学:从实验动物模型推断至人类行为毒理学研讨会综述
Neurotoxicol Teratol. 2012 Mar;34(2):263-73. doi: 10.1016/j.ntt.2012.01.008. Epub 2012 Jan 28.
7
Noradrenaline and Parkinson's disease.去甲肾上腺素与帕金森病。
Front Syst Neurosci. 2011 May 18;5:31. doi: 10.3389/fnsys.2011.00031. eCollection 2011.
8
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.托莫西汀治疗帕金森病执行功能障碍:一项开放性试点研究。
Mov Disord. 2009 Jan 30;24(2):277-82. doi: 10.1002/mds.22307.
9
Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats.去甲肾上腺素能对丘脑底核活动的调节:正常和6-羟基多巴胺损伤大鼠的行为和电生理证据
J Neurosci. 2007 Sep 5;27(36):9595-606. doi: 10.1523/JNEUROSCI.2583-07.2007.
10
Early Parkinson's disease: what is the best approach to treatment.早期帕金森病:最佳治疗方法是什么。
Drugs Aging. 2000 Sep;17(3):165-81. doi: 10.2165/00002512-200017030-00002.